- Report
- December 2022
- 109 Pages
Japan
From €1441EUR$1,530USD£1,200GBP
€1696EUR$1,800USD£1,412GBP
- Report
- September 2025
- 200 Pages
North America
From €2346EUR$2,490USD£1,953GBP
- Report
- November 2025
- 189 Pages
Global
From €4616EUR$4,900USD£3,844GBP
- Report
- December 2023
- 153 Pages
Global
From €2332EUR$2,475USD£1,941GBP
€4664EUR$4,950USD£3,883GBP
- Report
- November 2025
- 188 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- October 2025
- 192 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 194 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 188 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 180 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 196 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 190 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 184 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 191 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- August 2025
- 197 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- November 2021
- 256 Pages
Global
From €2473EUR$2,625USD£2,059GBP
€4946EUR$5,250USD£4,118GBP
- Report
- October 2024
- 200 Pages
Global
From €3533EUR$3,750USD£2,942GBP
- Report
- May 2024
- 200 Pages
Global
From €3910EUR$4,150USD£3,255GBP
- Report
- May 2024
- 200 Pages
Global
From €3910EUR$4,150USD£3,255GBP
- Report
- March 2024
- 200 Pages
Global
From €3910EUR$4,150USD£3,255GBP
- Report
- March 2024
- 200 Pages
Global
From €3910EUR$4,150USD£3,255GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more